Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

Abstract Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the treatment of acute lymphoblastic leukemia (ALL). The t(4;11)(q21;q23) chromosomal translocation that leads to the expr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tyler W. Jenkins, Sondra L. Downey-Kopyscinski, Jennifer L. Fields, Gilbert J. Rahme, William C. Colley, Mark A. Israel, Andrey V. Maksimenko, Steven N. Fiering, Alexei F. Kisselev
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/f287ffb014d44282a148d0dbf994ac53
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/f287ffb014d44282a148d0dbf994ac53

Ejemplares similares